From Intravenous to Subcutaneous Infliximab: the Same but Different? Real-World Evidence from a Tertiary Center

Authors

  • María José Temido Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra. https://orcid.org/0000-0002-0283-8507
  • Andrea Silva Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra.
  • Sandra Lópes Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra.
  • Ana Margarida Ferreira Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra.
  • Sofía Mendes Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra.
  • Manuela Ferreira Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra.
  • Pedro Figueiredo Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra. Faculty of Medicine, University of Coimbra.
  • Francisco Portela astroenterology Department, Centro Hospitalar e Universitário de Coimbra. Faculty of Medicine, University of Coimbra. https://orcid.org/0000-0002-7593-6124

DOI:

https://doi.org/10.52787/agl.v54i1.364

Keywords:

Crohn disease, ulcerative colitis, subcutaneous infliximab, intravenous infliximab, inflammatory bowel disease

Abstract

Introduction. Recently, a subcutaneous formulation of infliximab was approved. The switch from intravenous infliximab to subcutaneous infliximab may improve convenience, but data on pharmacokinetics and immunogenicity are limited. We aimed to compare the efficacy and tolerability of subcutaneous infliximab and to assess whether the formulation results in higher plasma levels of infliximab. 

Methods. Retrospective, single-center cohort study. Patients with Crohn’s disease or ulcerative colitis, 18 years of age or older, clinically stable, receiving intravenous infliximab (5mg/kg every eight weeks) for more than 6 months were switched. Subcutaneous infliximab (120 mg) was administered every 2 weeks. Clinical and analytical evaluations were performed on day 0, week 2, week 8, and week 16. Plasma levels of infliximab and anti-drug antibodies were measured at these time points. 

Results. 41 patients included (27 with Crohn’s disease and 14 with ulcerative colitis. Azathioprine was administered concomitantly in 47.6%. All patients remained in clinical remission. Analytical biomarkers remained stable. Treatment persistence: 95.1%. Median plasma levels of infliximab at day 0, week 2, week 8, and week 16: 4.89 (3.25 - 7.27), 9.17 (7.89 - 12.6), 19.91 (15.02 - 21.64) and 21.55 (17.18 - 29.57) ug/mL, respectively. Statistically significant difference of plasma levels of infliximab in day 0 vs. week 2 and week 2 vs week 8. Azathioprine resulted in a statistically significant difference in plasma levels of infliximab only at day 0 (not at week 2, week 8, or week 16). Plasma levels of infliximab at week 2, week 8, and week 16, but not at baseline, were statistically associated with body mass index. No anti-drug antibodies were detected. No severe adverse effects. Three patients developed injection site reactions. Three patients developed arthralgia of undetermined significance. 

Conclusions. Switching from intravenous infliximab to subcutaneous infliximab maintained clinical response. Plasma levels of infliximab at week two were still lower than expected, considering the results at week eight. A possible advantage of subcutaneous infliximab may be the diminished necessity for concomitant immunomodulators.

References

-1. Torres J, Mehandru S, Colombel J F, Peyrin-Biroulet L. Crohn’s disease. Lancet 2017;389:1741-55. https://DOI.org/10.1016/S0140-6736(16)31711-1

-2. Lasa J S, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2022;7:161-70. https://DOI.org/10.1016/S2468-1253(21)00377-0

-3. Raine T, Bonovas S, Burisch J, Torsten K, Bettenworth D, Chaparro M. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical treatment. J Crohn’s Colitis 2021;16:1-16. https://DOI.org/10.1093/ecco-jcc/jjab177

-4. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: Medical treatment. J Crohn’s Colitis 2020;14:4-22. https://DOI.org/10.1093/ecco-jcc/jjz180

-5. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019;114:384-413. https://DOI.org/10.14309/ajg.0000000000000152

-6. Lichtenstein GR, Loftus E V, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol 2018;113:481-517. https://DOI.org/10.1038/ajg.2018.27

-7. Buisson A, Serrero M, Orsat L, et al. Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study. Inflamm Bowel Dis 2022:4-6. https://DOI.org/10.1093/ibd/izac119

-8. European Medicines Agency. Remsima (Infliximab): summary of opinion (post authorisation) 2020.

-9. Buisson A, Nachury M, Reymond M, et al. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol 2022. https://DOI.org/10.1016/j.cgh.2022.08.011

-10. Verma AM, Patel A, Subramanian S, Smith PJ. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. Lancet Gastroenterol Hepatol 2021;6:88-9. https://DOI.org/10.1016/S2468-1253(20)30392-7

-11. Chaparro M, Garre A, Guerra Veloz MF, et al. Effectiveness and safety of the switch from remicade® to CT-P13 in patients with inflammatory bowel disease. J Crohn’s Colitis 2019;13:1380-6. https://DOI.org/10.1093/ecco-jcc/jjz070

-12. Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 2021;160:2340-53. https://DOI.org/10.1053/j.gastro.2021.02.068

-13. Smith PJ, Critchley L, Storey D, et al. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. J Crohns Colitis 2022;16:1436-46. https://DOI.org/10.1093/ecco-jcc/jjac053

-14. Huguet JM, García-Lorenzo V, Martí L, et al. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines 2022;10:1-11. https://DOI.org/10.3390/biomedicines10092130

-15. Roblin X, Veyrard P, Bastide L, Berger A, Barrau M. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn’s disease. Aliment Pharmacol Ther 2022;56:77-83;10.1111/apt.16852

-16. Colombel JF, Sandborn W, Reinisch W, et al. Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease. N Engl J Med 2010;362:1383-95. https://DOI.org/10.1056/NEJMoa0904492

-17. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology 2018;155:337-346.e10. https://DOI.org/10.1053/j.gastro.2018.04.012

-18. Hanzel J, Bukkems LH, Gecse KB, D’Haens GR, Mathôt RAA. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther 2021;54:1309-19. https://DOI.org/10.1111/apt.16609

Downloads

Published

2024-03-25

How to Cite

Temido, M. J., Silva, A., Lópes, S., Ferreira, A. M., Mendes, S., Ferreira, M., Figueiredo, P., & Portela, F. (2024). From Intravenous to Subcutaneous Infliximab: the Same but Different? Real-World Evidence from a Tertiary Center. Acta Gastroenterológica Latinoamericana, 54(1), 56–54. https://doi.org/10.52787/agl.v54i1.364

Issue

Vol. 54 No. 1 (2024): Acta Gastroenterológica Latinoamericana

Section

Original Articles

License

Copyright (c) 2024 María José Temido, Andrea Silva, Sandra Lópes, Ana Margarida Ferreira, Sofía Mendes, Manuela Ferreira, Pedro Figueiredo, Francisco Portela

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.